Every material Form 8-K Chemed filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Chemed reported third-quarter 2024 revenue of $606.2 million, up 7.4%, and adjusted diluted EPS of $5.64, up 6.0%. The company said Roto-Rooter's revenue and adjusted EBITDA were softer than anticipated, and it revised full-year 2024 adjusted EPS guidance to $23.00 to $23.15, which implies a 13.3% to 14.0% increase over 2023's $20.30.
Q3 2024 revenue $606.2 million, up 7.4%; GAAP diluted EPS $5.00, up 1.4%; adjusted diluted EPS $5.64, up 6.0%
VITAS net patient revenue $391.4 million, up 17.3%; Roto-Rooter revenue $214.8 million, down 6.9%
Roto-Rooter adjusted EBITDA $56.4 million, down 15.8%; adjusted EBITDA margin 26.3%, down 275 basis points
Full-year 2024 adjusted EPS guidance $23.00 to $23.15; company repurchased 100,000 shares for $57.8 million in the quarter
Chemed reported second-quarter 2024 revenue of $595.9 million, up 7.6%, and GAAP diluted EPS of $4.65, up 32.5%. The company raised its full-year 2024 adjusted EPS estimate to $23.55-$23.80 from the prior $23.30-$23.70, a higher outlook for shareholders.
Q2 2024 revenue rose 7.6% to $595.9 million; adjusted diluted EPS was $5.47, up 34.1%
VITAS revenue rose 16.7% to $374.6 million, while Roto-Rooter revenue fell 5.0% to $221.3 million
2024 adjusted EPS guidance raised to $23.55-$23.80 from $23.30-$23.70
As of June 30, 2024, cash and cash equivalents were $222.9 million with no current or long-term debt
Chemed reported first-quarter 2024 revenue of $589.2 million, up 5.2%, and GAAP diluted EPS of $4.24, up 18.4%, with VITAS driving the gains while Roto-Rooter revenue fell 5.8%. The company reiterated its full-year 2024 adjusted EPS guidance range of $23.30 to $23.70 and said it will provide updated guidance with its June 30, 2024 results.
Consolidated revenue rose 5.2% to $589.2 million; adjusted diluted EPS was $5.20, up 21.5%.
VITAS net patient revenue rose 14.0% to $354.0 million, and its adjusted EBITDA excluding Medicare Cap rose 67.2% to $60.7 million.
Roto-Rooter revenue fell 5.8% to $235.2 million, and its adjusted EBITDA declined 15.6%.
Full-year 2024 adjusted EPS guidance of $23.30 to $23.70 was reiterated; cash and equivalents were $313.4 million at March 31, 2024, with no debt.
VITAS Healthcare, a wholly owned subsidiary of Chemed, completed its $85 million purchase of substantially all hospice operations and an assisted living facility from Covenant Health and Community Services, effective April 17, 2024. The purchase was made with cash on hand, and the filing does not report financial results from the acquired operations.
Purchase price: $85 million, structured as an asset purchase, funded with cash on hand
Covenant hospice operations span the Florida panhandle and Alabama, including Pensacola, Tallahassee, Panama City and Dothan markets
Transaction was first announced on March 13, 2024 and closed effective April 17, 2024
Chemed reported fourth-quarter 2023 revenue of $585.9 million, up 7.2%, with GAAP diluted EPS of $5.90, up 42.9%, and adjusted diluted EPS of $6.60, up 35.0%. The company gave 2024 adjusted diluted EPS guidance of $23.30 to $23.70, compared with $20.30 in 2023, while Roto-Rooter revenue fell 1.1% in the quarter.
Q4 2023 revenue rose 7.2% to $585.9 million; GAAP diluted EPS was $5.90 and adjusted diluted EPS was $6.60
VITAS net patient revenue rose 13.6% to $350.0 million; Roto-Rooter revenue fell 1.1% to $235.9 million
2024 guidance: adjusted diluted EPS of $23.30 to $23.70 versus $20.30 adjusted EPS in 2023
As of December 31, 2023, cash and cash equivalents were $264.0 million with no current or long-term debt
Chemed granted David P. Williams, who now serves as an advisor to the Chief Executive Officer, 6,424 Performance Share Units and agreed to pay him a monthly salary of $38,750. The units vest into company shares based on Chemed's total shareholder return over the next three calendar years, tying part of his pay to shareholder returns.
Grant of 6,424 Performance Share Units to David P. Williams, dated January 29, 2024
Monthly salary of $38,750 for his role as advisor to the CEO
Units vest into shares depending on total shareholder return over the next three calendar years
Company may terminate his employment on twelve months' written notice
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Chemed filing is on SEC EDGAR ↗. 8-K briefs of other companies →